Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year High – What’s Next?

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) reached a new 52-week high on Monday . The company traded as high as $48.45 and last traded at $46.9930, with a volume of 196079 shares. The stock had previously closed at $44.23.

Trending Headlines about Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Sionna Therapeutics and kept a $58 price target, implying meaningful upside from recent trading levels and reinforcing optimism around the company’s clinical pipeline. Article Title
• Positive Sentiment: Sionna Therapeutics said management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 20, which can give investors a fresh update on the company’s cystic fibrosis programs and keep attention on the story. Article Title
• Neutral Sentiment: In its first-quarter update, the company said enrollment is complete in the PreciSION CF Phase 2a trial for SION-719 and that topline data is expected in summer 2026, while the SION-451 Phase 1 study is also on track. It also reported a strong cash balance of about $289.9 million, supporting operations into 2028. Article Title
• Negative Sentiment: Sionna reported a first-quarter loss of $0.60 per share, wider than the expected $0.52 loss, which may weigh on sentiment even though the company remains pre-revenue and focused on clinical development. Article Title
• Negative Sentiment: Director OrbiMed Advisors and director Peter A. Thompson disclosed several large share sales in recent days. The transactions were made under pre-arranged 10b5-1 plans, but the size of the selling can still pressure investor sentiment. Article Title

Analysts Set New Price Targets

A number of research firms have weighed in on SION. Wedbush began coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective on the stock. Citigroup began coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They set an “outperform” rating on the stock. JonesTrading raised their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Wednesday. Finally, Guggenheim raised their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.00.

Sionna Therapeutics Trading Up 5.3%

The business’s 50-day moving average price is $38.93 and its 200-day moving average price is $39.48.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, research analysts predict that Sionna Therapeutics, Inc. will post -2.32 EPS for the current year.

Insider Buying and Selling

In other news, Director Peter A. Thompson sold 235,863 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares in the company, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,717,760 shares of company stock worth $77,562,902. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics in the 4th quarter valued at $36,000. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics in the 3rd quarter valued at $30,000. Balyasny Asset Management L.P. purchased a new position in Sionna Therapeutics in the 4th quarter valued at $58,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the 2nd quarter valued at $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics in the 4th quarter valued at $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.